Congratulations to CEO, Monica Dudley-Weldon
Monica Dudley-Weldon, President, CEO & Founder of SYNGAP1 Foundation, is a true professional in a challenging and competitive business, standing on the same podium as world-renowned corporate and key opinion leaders.
Bridge the Gap - SYNGAP Education and Research Foundation Presents Their First ResearchGrant to Kennedy Krieger Institute
SYNGAP Education and Research Foundation presented Kennedy Krieger Institute, in academic affiliation with the Johns Hopkins University School of Medicine, with their first research grant of $25,000 on January 23, 2019.
Bridge the Gap - SYNGAP: Families aid discovery of a sensory-processing disorder in broken gene in children with autism traits
A concerned Texas mom finally has answers about the cause of her son's sensory-processing problems thanks to a special collaboration among her patient-advocacy group and the lab of Scripps Research Neuroscientist Gavin Rumbaugh, PhD.
Bridge the Gap - SYNGAP Education and Research Foundation Presents Their First Research Grant to Texas Children's Hospital
Bridge the Gap - SYNGAP Education and Research Foundation awarded its first research grant of $25,000 to Texas Children’s Hospital.
From Bench T0 Bedside And Back
Neuroscientist Richard Huganir studies a genetic mutation that contributes to intellectual disability
Rare Disease Report Strategic Alliance Partner Publishes Syngap-1 Paper
Monica Weldon, CEO, President and Founder of Bridge the Gap: SYNGAP Education and Research Foundation – one of Rare Disease Report’s Strategic Alliance Partners (SAP) – has made her debut as the lead author on a scientific paper.
Rare Disease Foundation CEO cites collaboration, data sharing as keys to progress
Monica Weldon, a mother, teacher, and rare disease advocate from Houston, founded Bridge the Gap - SYNGAP Education and Research Foundation after her son Beckett was diagnosed with SYNGAP1, underscoring the importance of genetic testing and research in understanding rare conditions.
World’s Largest-Ever Study of SYNGAP1 (MRD5) Launches
Bridge the Gap – SYNGAP Education and Research Foundation has launched the largest-ever SYNGAP1 study, aiming to understand the condition's complexities and provide critical insights for research towards a cure, underscoring the urgent need for solutions in addressing the intellectual disability, speech delay, and other challenges associated with SYNGAP1.
Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program
This program is a crucial incentive--in addition to the Orphan Drug Act--for drug manufacturers to invest significantly in developing therapies for rare pediatric diseases, including pediatric cancers and lysosomal storage disorders.